Drug Information

Drug General Information
Drug ID
D07NBA
Former ID
DNCL001564
Drug Name
Veltuzumab
Drug Type
Monoclonal antibody
Indication Chronic lymphocytic leukaemia; Non-hodgkin's lymphoma; Systemic lupus erythematosus [ICD9: 710; ICD10:C91, C85, M32] Phase 2 [523540], [543023]
Company
Takeda
CAS Number
CAS 728917-18-8
Target and Pathway
Target(s) B-lymphocyte antigen CD20 Target Info Modulator [530047]
KEGG Pathway Hematopoietic cell lineage
References
Ref 523540ClinicalTrials.gov (NCT01390545) VELVET, a Dose Range Finding Trial of Veltuzumab in Subjects With Moderate to Severe Rheumatoid Arthritis. U.S. National Institutes of Health.
Ref 543023(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8268).
Ref 530047Veltuzumab, an anti-CD20 mAb for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and immune thrombocytopenic purpura. Curr Opin Mol Ther. 2009 Apr;11(2):200-7.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.